These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 29582559

  • 21. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2.
    Giangrande P, Abdul Karim F, Nemes L, You CW, Landorph A, Geybels MS, Curry N.
    J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):5-14. PubMed ID: 32544297
    [Abstract] [Full Text] [Related]

  • 22. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
    Chowdary P, Fischer K, Collins PW, Cotterill A, Konkle BA, Blanchette V, Pipe SW, Berntorp E, Wolfsegger M, Engl W, Spotts G.
    Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844
    [Abstract] [Full Text] [Related]

  • 23. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.
    Shetty KA, Kosloski MP, Mager DE, Balu-Iyer SV.
    J Pharm Sci; 2015 Feb; 104(2):388-95. PubMed ID: 24700333
    [Abstract] [Full Text] [Related]

  • 24. Half-life extended factor VIII for the treatment of hemophilia A.
    Tiede A.
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S176-9. PubMed ID: 26149020
    [Abstract] [Full Text] [Related]

  • 25. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A.
    Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J.
    J Thromb Haemost; 2014 Apr; 12(4):488-96. PubMed ID: 24843882
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)).
    Pastoft AE, Lykkesfeldt J, Ezban M, Tranholm M, Whinna HC, Lauritzen B.
    Haemophilia; 2012 Sep; 18(5):782-8. PubMed ID: 22500820
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF.
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs.
    Karpf DM, Kjalke M, Thim L, Agersø H, Merricks EP, Defriess N, Nichols TC, Ezban M.
    Haemophilia; 2011 Sep; 17(5):e963-8. PubMed ID: 21682818
    [Abstract] [Full Text] [Related]

  • 31. Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules.
    Johansen PB, Tranholm M, Haaning J, Knudsen T.
    Haemophilia; 2016 Jul; 22(4):625-31. PubMed ID: 26936336
    [Abstract] [Full Text] [Related]

  • 32. Cases of less-than-expected FVIII activity in previously treated patients during post-marketing surveillance of N8-GP.
    Oldenburg J, Benson G, Chowdary P, Halimeh S, Matsushita T, Nørland A, Wahid MN, Nemes L.
    Haemophilia; 2023 Nov; 29(6):1475-1482. PubMed ID: 37729439
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.
    Elm T, Karpf DM, Øvlisen K, Pelzer H, Ezban M, Kjalke M, Tranholm M.
    Haemophilia; 2012 Jan; 18(1):139-45. PubMed ID: 21771205
    [Abstract] [Full Text] [Related]

  • 34. Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct®).
    Bjørnsdottir I, Støvring B, Søeborg T, Jacobsen H, Sternebring O.
    Drugs R D; 2020 Jun; 20(2):75-82. PubMed ID: 32152818
    [Abstract] [Full Text] [Related]

  • 35. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
    Nestorov I, Neelakantan S, Ludden TM, Li S, Jiang H, Rogge M.
    Clin Pharmacol Drug Dev; 2015 Jun; 4(3):163-74. PubMed ID: 27140796
    [Abstract] [Full Text] [Related]

  • 36. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T.
    Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
    [Abstract] [Full Text] [Related]

  • 37. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A, Coyle T, Lalezari S, Fischer K, Kohlstaedde B, Delesen H, Radke S, Michaels LA.
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [Abstract] [Full Text] [Related]

  • 38. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
    Male C, Königs C, Dey S, Matsushita T, Millner AH, Zak M, Young G, Kenet G.
    Blood Adv; 2023 Feb 28; 7(4):620-629. PubMed ID: 35858373
    [Abstract] [Full Text] [Related]

  • 39. Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans.
    Kim MS, Hajducek DM, Gilbert JC, Iorio A, Jilma B, Edginton AN.
    AAPS J; 2024 Jul 12; 26(4):81. PubMed ID: 38992298
    [Abstract] [Full Text] [Related]

  • 40. Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Shah A, Solms A, Wiegmann S, Ahsman M, Berntorp E, Tiede A, Iorio A, Mancuso ME, Zhivkov T, Lissitchkov T.
    Ann Hematol; 2019 Sep 12; 98(9):2035-2044. PubMed ID: 31236667
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.